However, the combination of cabiralizumab, a CSF-1R blocking monoclonal antibody, with chemotherapy and nivolumab in metastatic PC patients did not improve PFS with respect to chemotherapy alone in a phase II study. This evidence concerns the gene CSF1R and pachyonychia congenita.